» Articles » PMID: 24521710

A Global Profile of Gene Promoter Methylation in Treatment-naïve Urothelial Cancer

Overview
Journal Epigenetics
Specialty Genetics
Date 2014 Feb 14
PMID 24521710
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The epigenetic alteration of aberrant hypermethylation in the promoter CpG island of a gene is associated with repression of transcription. In neoplastic cells, aberrant hypermethylation is well described as a mechanism of allele inactivation of particular genes with a tumor suppressor function. To investigate the role of aberrant hypermethylation in the biology and progression of urothelial cancer, we examined 101 urothelial (transitional cell) carcinomas (UC), broadly representative of the disease at presentation, with no prior immunotherapy, chemotherapy or radiotherapy, by Infinium HM27 containing 14,495 genes. The genome-wide signature of aberrant promoter hypermethylation in UC consisted of 729 genes significant by a Wilcoxon test, hypermethylated in a CpG island within 1 kb of the transcriptional start site and unmethylated in normal urothelium from aged individuals. We examined differences in gene methylation between the two main groups of UC: the 75% that are superficial, which often recur but rarely progress, and the 25% with muscle invasion and poor prognosis. We further examined pairwise comparisons of the pathologic subgroups of high or low grade, invasive or non-invasive (pTa), and high grade superficial or low grade superficial UC. Pathways analysis indicated over-representation of genes involved in cell adhesion or metabolism in muscle-invasive UC. Notably, the TET2 epigenetic regulator was one of only two genes more frequently methylated in superficial tumors and the sole gene in low grade UC. Other chromatin remodeling genes, MLL3 and ACTL6B, also showed aberrant hypermethylation. The Infinium methylation value for representative genes was verified by pyrosequencing. An available mRNA expression data set indicated many of the hypermethylated genes of interest to be downregulated in UC. Unsupervised clustering of the most differentially methylated genes distinguished muscle invasive from superficial UC. After filtering, cluster analysis showed a CpG Island Methylator Phenotype (CIMP)-like pattern of widespread methylation in 11 (11%) tumors. Nine of these 11 tumors had hypermethylation of TET2. Our analysis provides a basis for further studies of hypermethylation in the development and progression of UC.

Citing Articles

Anti-Cancer Effects and Tumor Marker Role of Glutathione -Transferase Mu 5 in Human Bladder Cancer.

Jou Y, Wang S, Dia Y, Wang S, Yu M, Yang H Int J Mol Sci. 2021; 22(6).

PMID: 33802702 PMC: 8002531. DOI: 10.3390/ijms22063056.


Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.

Quinn D, Tsao-Wei D, Twardowski P, Aparicio A, Frankel P, Chatta G Invest New Drugs. 2021; 39(3):812-820.

PMID: 33409898 DOI: 10.1007/s10637-020-01038-6.


Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.

Poreba E, Lesniewicz K, Durzynska J Int J Mol Sci. 2020; 21(24).

PMID: 33302406 PMC: 7762615. DOI: 10.3390/ijms21249340.


Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.

Larsson C, Cordeddu L, Siggens L, Pandzic T, Kundu S, He L Clin Epigenetics. 2020; 12(1):74.

PMID: 32471474 PMC: 7257146. DOI: 10.1186/s13148-020-00863-z.


The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.

Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z EMBO Rep. 2019; 20(3).

PMID: 30665945 PMC: 6399616. DOI: 10.15252/embr.201846821.


References
1.
Kim Y, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M . TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol. 2011; 64(10):850-2. DOI: 10.1136/jclinpath-2011-200133. View

2.
Bharti S, Handrow-Metzmacher H, Zickenheiner S, Zeitvogel A, Baumann R, Starzinski-Powitz A . Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells. Mol Biol Cell. 2003; 15(1):397-406. PMC: 307556. DOI: 10.1091/mbc.e03-05-0281. View

3.
Li D, Da L, Tang H, Li T, Zhao M . CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding. Nucleic Acids Res. 2007; 36(1):330-41. PMC: 2248752. DOI: 10.1093/nar/gkm1028. View

4.
Hinoue T, Weisenberger D, Lange C, Shen H, Byun H, van den Berg D . Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2011; 22(2):271-82. PMC: 3266034. DOI: 10.1101/gr.117523.110. View

5.
Byun H, Siegmund K, Pan F, Weisenberger D, Kanel G, Laird P . Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. Hum Mol Genet. 2009; 18(24):4808-17. PMC: 4481584. DOI: 10.1093/hmg/ddp445. View